We tested the Raboral V-RG® recombinant oral rabies vaccine for its response in Arctic foxes (Vulpes lagopus), the reservoir of rabies virus in the circumpolar North. The vaccine, which is currently the only licensed oral rabies vaccine in the United States, induced a strong antibody response and protected foxes against a challenge of 500,000 mouse intracerebral lethal dose 50% of an Arctic rabies virus variant. However, one unvaccinated control fox survived challenge with rabies virus, either indicating a high resistance of Arctic foxes to rabies infection or a previous exposure that induced immunity. This preliminary study suggested that Raboral V-RG vaccine may be efficacious in Arctic foxes.
How to translate text using browser tools
1 October 2011
Preliminary Evaluation of Raboral V-RG® Oral Rabies Vaccine in Arctic Foxes (Vulpes lagopus)
Erich Follmann,
Don Ritter,
Rhonda Swor,
Mike Dunbar,
Karsten Hueffer
ACCESS THE FULL ARTICLE
Journal of Wildlife Diseases
Vol. 47 • No. 4
October 2011
Vol. 47 • No. 4
October 2011
Arctic fox
oral vaccination
rabies
recombinant vaccine